Twist Bioscience Corporation experienced a significant surge in its stock value on Monday, following the release of its first-quarter 2026 financial results. The company reported a loss of 50 cents per share, aligning with Wall Street forecasts. However, its revenue considerably surpassed expectations, reaching $103.70 million, marking a 17% increase from the previous year and exceeding the consensus estimate of $102.72 million.
During this quarter, Twist Bioscience expanded its customer base, shipping products to approximately 2,538 clients, an increase from 2,376 in the prior year. The company also saw a substantial rise in gene shipments, with approximately 271,000 genes delivered compared to 205,000 last year, a portion of which was dedicated to data characterization. The gross margin improved to 52% from 48.3% in the previous year, and the adjusted EBITDA loss decreased to $13.4 million, demonstrating a positive financial trend. As of December 31, 2025, the company maintained a healthy cash position with approximately $198 million in cash, cash equivalents, and short-term investments.
Looking ahead, Twist Bioscience's CEO, Emily Leproust, expressed confidence in the company's trajectory towards profitability, emphasizing consistent revenue growth, gross margins above 50%, and strategic investments in scalable growth opportunities. The company has revised its fiscal 2026 sales guidance upwards to between $435 million and $440 million, surpassing the market consensus. This optimistic outlook is supported by expected balanced revenue increases across its Digital Sequence Preservation Solutions (DSPS) and Next-Generation Sequencing (NGS) segments, with a projected gross margin exceeding 52% for the fiscal year. Twist Bioscience anticipates achieving adjusted EBITDA breakeven by the fourth quarter of fiscal 2026 and expects second-quarter sales to be between $107 million and $108 million.
The company's strong performance and forward-looking strategy reflect a commitment to innovation and market expansion. Through diligent financial management and a focus on core competencies, Twist Bioscience is well-positioned to continue its upward trajectory, benefiting both its stakeholders and the broader scientific community by advancing genetic research and biotech science.
